 |
|
Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
Won Seop Kim (Kim WS)
Clin Exp Pediatr. 2011;54(6):241-245. Published online 2011 Jun 30 DOI: https://doi.org/10.3345/kjp.2011.54.6.241
|
|
Citations to this article as recorded by
 Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
Katarzyna Łukasiuk, Władysław Lasoń
International Journal of Molecular Sciences.2023; 24(3): 2928. CrossRef Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
Shanshan Mao, Qi Long, Huijia Lin, Jinling Liu
Experimental and Therapeutic Medicine.2017;[Epub] CrossRef Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats
Wanchun You, Zhong Wang, Haiying Li, Haitao Shen, Xiang Xu, Genlai Jia, Gang Chen
Journal of the Neurological Sciences.2016; 367: 224. CrossRef Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex
Àlex Rovira, María Luz Ruiz-Falcó, Elena García-Esparza, Eduardo López-Laso, Alfons Macaya, Ignacio Málaga, Élida Vázquez, Josefina Vicente
Journal of Neuro-Oncology.2014; 118(2): 205. CrossRef Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
Won Seop Kim
Korean Journal of Pediatrics.2013; 56(6): 269. CrossRef
|